Literature DB >> 33413186

Prevalence of Salmonella enterica serovar Typhi infection, its associated factors and antimicrobial susceptibility patterns among febrile patients at Adare general hospital, Hawassa, southern Ethiopia.

Roza Nasir Awol1, Dawit Yihdego Reda2, Deresse Daka Gidebo2.   

Abstract

BACKGROUND: Salmonellas enterica serovar Typhi (S.typhi) causes typhoid fever and is a global health problem, especially in developing countries like Ethiopia. But there is a little information about prevalence and factors association with S.typhi and its antimicrobial susceptibility pattern in Ethiopia especially in the study area. The aim of this study was to determine the prevalence of S.typhi infection, its associated factors and antimicrobial susceptibility pattern among patient with a febrile illness at Adare General Hospital, Hawassa, Southern Ethiopia.
METHODS: Hospital based cross sectional study was conducted among 422 febrile patients from May 23, 2018 to October 20, 2018. A 5 ml venous blood was collected from each febrile patient. Culture and biochemical test were performed for each isolate. Antimicrobial susceptibility testing was performed for each isolate using modified Kirby-Bauer disk diffusion techniques. RESULT: In this study, the prevalence of S.typhi among febrile illness patients at Adare General Hospital was 1.6% [95% confidence interval (CI): 0.5-2.9]. The age of the study subjects were ranged from 15 to 65 years (mean age 32 years). It was observed that participants who came from rural area had 8 times (AOR 8.27: 95% CI: 1.33, 51.55) more likely to had S. typhi infection when compared with urban dwellers. The microbial susceptibility testing revealed that all six of S.typhi isolates showed sensitive to Ceftriaxone and all 6 isolates showed resistant to nalidixic acid and Cefotaxime and 5(83.3%) susceptible to Chloramphenicol and Ciprofloxaciline. Multidrug resistance (resistance to three or more antibiotics) was observed among most of the isolates.
CONCLUSION: S. typhi bacteraemia is an uncommon but important cause of febrile illness in our study population. Ceftriaxone therapy is a suitable empirical antibiotic for those that are unwell and suspected of having this illness. Further surveillance is required to monitor possible hanging antibiotic resistant patterns in Ethiopia.

Entities:  

Keywords:  Ethiopia; Febrile patient; Hawassa; S.typhi

Mesh:

Substances:

Year:  2021        PMID: 33413186      PMCID: PMC7791979          DOI: 10.1186/s12879-020-05726-9

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  18 in total

Review 1.  Water, sanitation, and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-analysis.

Authors:  Lorna Fewtrell; Rachel B Kaufmann; David Kay; Wayne Enanoria; Laurence Haller; John M Colford
Journal:  Lancet Infect Dis       Date:  2005-01       Impact factor: 25.071

Review 2.  Role of antigens and virulence factors of Salmonella enterica serovar Typhi in its pathogenesis.

Authors:  Jasmine Kaur; S K Jain
Journal:  Microbiol Res       Date:  2011-09-25       Impact factor: 5.415

3.  Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise.

Authors:  M L Ackers; N D Puhr; R V Tauxe; E D Mintz
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

4.  Antimicrobial susceptibility patterns of Salmonella typhi and Salmonella paratyphi A in a tertiary care hospital.

Authors:  S Raza; R Tamrakar; C P Bhatt; S K Joshi
Journal:  J Nepal Health Res Counc       Date:  2012-09

5.  Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia.

Authors:  Albert M Vollaard; Soegianto Ali; Henri A G H van Asten; Suwandhi Widjaja; Leo G Visser; Charles Surjadi; Jaap T van Dissel
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

6.  Risk factors for enteric perforation in patients with typhoid Fever.

Authors:  Salih Hosoglu; Mustafa Aldemir; Serife Akalin; Mehmet Faruk Geyik; Ibrahim H Tacyildiz; Mark Loeb
Journal:  Am J Epidemiol       Date:  2004-07-01       Impact factor: 4.897

Review 7.  Typhoid fever in Ethiopia.

Authors:  Getenet Beyene; Daniel Asrat; Yohannes Mengistu; Abrham Aseffa; John Wain
Journal:  J Infect Dev Ctries       Date:  2008-12-01       Impact factor: 0.968

8.  Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment.

Authors:  Vittal Mogasale; Brian Maskery; R Leon Ochiai; Jung Seok Lee; Vijayalaxmi V Mogasale; Enusa Ramani; Young Eun Kim; Jin Kyung Park; Thomas F Wierzba
Journal:  Lancet Glob Health       Date:  2014-10       Impact factor: 26.763

9.  Typhoid Fever and its association with environmental factors in the Dhaka Metropolitan Area of Bangladesh: a spatial and time-series approach.

Authors:  Ashraf M Dewan; Robert Corner; Masahiro Hashizume; Emmanuel T Ongee
Journal:  PLoS Negl Trop Dis       Date:  2013-01-24

10.  Bacterial profile and antimicrobial susceptibility pattern in septicemia suspected patients attending Gondar University Hospital, Northwest Ethiopia.

Authors:  Mulat Dagnew; Gizachew Yismaw; Mucheye Gizachew; Alemayehu Gadisa; Tigist Abebe; Tinebeb Tadesse; Agersew Alemu; Biniam Mathewos
Journal:  BMC Res Notes       Date:  2013-07-22
View more
  2 in total

Review 1.  Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?

Authors:  Samuel Kariuki; Kelvin Kering; Celestine Wairimu; Robert Onsare; Cecilia Mbae
Journal:  Infect Drug Resist       Date:  2022-07-07       Impact factor: 4.177

2.  Prevalence and antimicrobial susceptibility level of typhoid fever in Ethiopia: A systematic review and meta-analysis.

Authors:  Melese Yeshambaw Teferi; Ziad El-Khatib; Endawoke Amsalu Alemayehu; Hawult Taye Adane; Azeb Tarekegn Andualem; Yonas Abebe Hailesilassie; Abraham Sahilemichael Kebede; Benedict Oppong Asamoah; Minyahil Tadesse Boltena; Mulatu Biru Shargie
Journal:  Prev Med Rep       Date:  2021-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.